drugset
drugset / Trial / NCT06945445

Study of SLN12140 in Healthy Adult Participants

NCT06945445 ↗

Phase 1 Not yet recruiting 56 enrolled Linno Pharmaceuticals, Inc.
RandomizedParallel-groupTriple-blindTreatment

Summary

A randomized, double-blind, placebo-controlled phase I clinical study evaluating the safety, tolerability, pharmacokinetics, pharmacodynamics, and immunogenicity of SLN12140 in healthy participants with single subcutaneous/intravenous dose escalation and multiple subcutaneous administrations

Timeline

Start
2025-04
Primary completion
2026-05
Completion
2026-06

Drugs

EvaluationDrugModalityDoseRoute
Subject SLN12140 Unknown 50 mg Subcutaneous
Subject SLN12140 Unknown 150 mg Subcutaneous
Subject SLN12140 Unknown 450 mg Subcutaneous
Subject SLN12140 Unknown 900 mg Subcutaneous
Subject SLN12140 Unknown 1500 mg Subcutaneous
Subject SLN12140 Unknown 1800 mg Subcutaneous

Indications

No indication recorded.